These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 8471836)

  • 1. Immunological and clinical effects of intramuscular rIFN alpha-2a and low dose subcutaneous rIL-2 in patients with advanced malignant melanoma.
    Castello G; Comella P; Manzo T; Napolitano M; Parziale AP; Galati MG; Daponte A; Casaretti R; Celentano E; Comella G
    Melanoma Res; 1993 Feb; 3(1):43-9. PubMed ID: 8471836
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expansion of peripheral blood natural killer cells correlates with clinical outcome in cancer patients receiving recombinant subcutaneous interleukin-2 and interferon-alpha-2.
    Atzpodien J; Kirchner H; Körfer A; Hadam M; Schomburg A; Menzel T; Deckert M; Franzke A; Volkenandt M; Dallmann I
    Tumour Biol; 1993; 14(6):354-9. PubMed ID: 8265981
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low-dose interleukin-2 in combination with interferon-alpha effectively modulates biological response in vivo.
    Schneekloth C; Körfer A; Hadam M; Lopez Hänninen E; Menzel T; Schomburg A; Dallmann I; Kirchner H; Poliwoda H; Atzpodien J
    Acta Haematol; 1993; 89(1):13-21. PubMed ID: 7683166
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunological evaluation of patients with hematological malignancies receiving ambulatory cytokine-mediated immunotherapy with recombinant human interferon-alpha 2a and interleukin-2.
    Morecki S; Revel-Vilk S; Nabet C; Pick M; Ackerstein A; Nagler A; Naparstek E; Ben Shahar M; Slavin S
    Cancer Immunol Immunother; 1992; 35(6):401-11. PubMed ID: 1394343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adoptive immunotherapy with tumor-infiltrating lymphocytes and subcutaneous recombinant interleukin-2 plus interferon alfa-2a for melanoma patients with nonresectable distant disease: a phase I/II pilot trial. Melanoma Istituto Scientifico Tumori Group.
    Queirolo P; Ponte M; Gipponi M; Cafiero F; Peressini A; Semino C; Pietra G; Lionetto R; Vecchio S; Ribizzi I; Melioli G; Sertoli MR
    Ann Surg Oncol; 1999; 6(3):272-8. PubMed ID: 10340886
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Daily alternating administration of high-dose alpha-2b-interferon and interleukin-2 bolus infusion in metastatic renal cell cancer. A phase II study.
    Bergmann L; Fenchel K; Weidmann E; Enzinger HM; Jahn B; Jonas D; Mitrou PS
    Cancer; 1993 Sep; 72(5):1733-42. PubMed ID: 8348502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-dose integrated chemoimmuno-hormonotherapy with cisplatin, subcutaneous interleukin-2, alpha-interferon and tamoxifen for advanced metastatic melanoma--a pilot study.
    Bernengo MG; Doveil GC; Bertero M; Quaglino P; Fierro MT; Savoia P; Appino A; Colonna S
    Melanoma Res; 1996 Jun; 6(3):257-65. PubMed ID: 8819129
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I clinical trial of interleukin 2 and alpha-interferon: toxicity and immunologic effects.
    Budd GT; Osgood B; Barna B; Boyett JM; Finke J; Medendorp SV; Murthy S; Novak C; Sergi J; Tubbs R
    Cancer Res; 1989 Nov; 49(22):6432-6. PubMed ID: 2804986
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Chemo-/immunotherapy in advanced malignant melanoma: carboplatin and DTIC or cisplatin, dtic, bcnu and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha-2a].
    Kirchner HH; Atzpodien J; Poliwoda H
    Med Klin (Munich); 1996 Apr; 91 Suppl 3():44-9. PubMed ID: 8692119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term treatment with low doses of interleukin-2 and interferon-alpha: immunological effects in advanced renal cell cancer.
    Pavone L; Andrulli S; Santi R; Majori M; Buzio C
    Cancer Immunol Immunother; 2001 Apr; 50(2):82-6. PubMed ID: 11401029
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biological monitoring of low-dose interleukin 2 in humans: soluble interleukin 2 receptors, cytokines, and cell surface phenotypes.
    Hänninen EL; Körfer A; Hadam M; Schneekloth C; Dallmann I; Menzel T; Kirchner H; Poliwoda H; Atzpodien J
    Cancer Res; 1991 Dec; 51(23 Pt 1):6312-6. PubMed ID: 1933892
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Independent expression of p55 and p75 interleukin-2 receptors (IL-2R) during intravenous or subcutaneous administration of recombinant interleukin-2 (rIL-2) by T-lymphocytes and natural killer cells.
    Zambello R; Trentin L; Cerutti A; Enthammer C; Milani A; Franceschi T; Messina C; Cetto GL; Agostini C; Semenzato G
    Cancer; 1994 Nov; 74(9):2562-9. PubMed ID: 7522954
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant immunotherapy in malignant melanoma: impact of antibody formation against interferon-alpha on immunoparameters in vivo.
    Davis-Daneshfar A; Böni R; von Wussow P; Joller H; Burg G; Dummer R
    J Immunother; 1997 May; 20(3):208-13. PubMed ID: 9181459
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and immune modulatory effects of alternative weekly interleukin-2 and interferon alfa-2a in patients with advanced renal cell carcinoma and melanoma.
    Pichert G; Jost LM; Fierz W; Stahel RA
    Br J Cancer; 1991 Feb; 63(2):287-92. PubMed ID: 1997108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo regulation of transforming growth factor beta 1 transcription by immunotherapy: interleukin-2 impairs interferon-alpha-stimulated increase in steady-state mRNA levels of transforming growth factor beta 1.
    Jahn B; Brieger J; Fenchel K; Mitrou PS; Bergmann L
    Cancer Immunol Immunother; 1994 May; 38(5):304-10. PubMed ID: 8162612
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemoimmunotherapy of advanced malignant melanoma: sequential administration of subcutaneous interleukin-2 and interferon-alpha after intravenous dacarbazine and carboplatin or intravenous dacarbazine, cisplatin, carmustine and tamoxifen.
    Atzpodien J; Lopez Hänninen E; Kirchner H; Franzke A; Körfer A; Volkenandt M; Duensing S; Schomburg A; Chaitchik S; Poliwoda H
    Eur J Cancer; 1995 Jun; 31A(6):876-81. PubMed ID: 7646914
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of interferon alfa in the treatment of metastatic melanoma.
    Legha SS
    Semin Oncol; 1997 Feb; 24(1 Suppl 4):S24-31. PubMed ID: 9122731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Natural killer cell cytotoxicity is enhanced by very low doses of rIL-2 and rIFN-alpha in patients with renal cell carcinoma.
    Pavone L; Fanti G; Bongiovanni C; Goldoni M; Alberici F; Bonomini S; Cristinelli L; Buzio C
    Med Oncol; 2009; 26(1):38-44. PubMed ID: 18516705
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
    Freedman RS; Kudelka AP; Kavanagh JJ; Verschraegen C; Edwards CL; Nash M; Levy L; Atkinson EN; Zhang HZ; Melichar B; Patenia R; Templin S; Scott W; Platsoucas CD
    Clin Cancer Res; 2000 Jun; 6(6):2268-78. PubMed ID: 10873077
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative study on the effects of recombinant alpha-2 interferon on immune function in patients with disseminated melanoma.
    Hersey P; Coates A; Rallings M; Hall C; MacDonald M; Spurling A; Edwards A; McCarthy WH; Milton GW
    J Biol Response Mod; 1986 Jun; 5(3):236-49. PubMed ID: 3487622
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.